Online citations, reference lists, and bibliographies.
← Back to Search

Modification Of Tumor Cells By A Low Dose Of Newcastle Disease Virus.

Paul Von Hoegen, E. Weber, V. Schirrmacher
Published 1989 · Medicine, Biology

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The present study elucidates the mechanism whereby viral xenogenization of highly metastatic ESb lymphoid tumor cells increases tumor immunogenicity and syngeneic tumor‐specific T cell responses in comparison to nonmodified tumor cells. It was found that the frequency of cytotoxic T lymphocytes specific for the ESb tumor‐associated transplantation antigen (TATA) and the cytotoxic anti‐tumor activity in bulk cultures of immune spleen cells were significantly increased (by factor 3 and 25, respectively) when using virus‐modified tumor cells. An amplified response was observed both in vivo and in vitro which might explain the demonstrated effectiveness of this approach for postoperative immunotherapy of ESb metastases.
This paper references
10.1002/EJI.1830131012
Somatic H‐2Kk variants reveal nonidentity of serological and cytotoxic T cell‐defined Kk determinants
H. Vohr (1983)
10.1111/j.1365-3083.1985.tb01438.x
Virus‐Dependent Cellular Cytotoxicity in Vitro
A. Alsheikhly (1985)
Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.
P. Altevogt (1984)
10.1016/S0065-230X(08)60900-8
Virus augmentation of the antigenicity of tumor cell extracts.
F. C. Austin (1979)
10.1002/EJI.1830171231
CD4+ helper T cells are required for resistance to a highly metastatic murine tumor
H. Schild (1987)
10.1016/0022-1759(84)90320-X
A method for testing the specificity of influenza A virus-reactive memory cytotoxic T lymphocyte (CTL) clones in limiting dilution cultures.
U. Kees (1984)
The biological modification of tumor cells as a means of inducing their regression: an overview.
H. Kobayashi (1986)
10.1016/0022-1759(83)90303-4
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
T. Mosmann (1983)
10.1128/JB.92.4.862-868.1966
Interferon production by inactivated Newcastle disease virus in cell cultures and in mice.
J. Youngner (1966)
10.1084/JEM.154.2.557
Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes
K. Bosslet (1981)
10.1038/315301A0
Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection
R. Wallich (1985)
T cell growth factor: parameters of production and a quantitative microassay for activity.
S. Gillis (1978)
10.1016/0022-1759(85)90036-5
A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies.
K. Heeg (1985)
10.1093/OXFORDJOURNALS.JBCHEM.A135164
Gangliosides as paramyxovirus receptor. Structural requirement of sialo-oligosaccharides in receptors for hemagglutinating virus of Japan (Sendai virus) and Newcastle disease virus.
Y. Suzuki (1985)
T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
Y. Takai (1985)
10.1002/IJC.2910230216
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes
V. Schirrmacher (1979)
10.1016/S0065-230X(08)60899-4
Viral xenogenization of intact tumor cells.
H. Kobayashi (1979)
The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.
H. Fujiwara (1980)
Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.
M. Hosokawa (1983)
Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells.
D. Y. Sia (1984)
10.1080/01621459.1963.10500843
Ordered Hypotheses for Multiple Treatments: A Significance Test for Linear Ranks
E. B. Page (1963)
10.1002/IJC.2910370416
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects
R. Heicappell (1986)
Effects of mutagens on the immunogenicity of murine tumor cells: immunological and biochemical evidence for altered cell surface antigens.
P. Altevogt (1985)
10.1038/314098A0
Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells
R. Ceredig (1985)
Control of immune interferon release by cytotoxic T-cell clones specific for influenza.
P. M. Taylor (1985)
10.3109/08820137609047620
Associative control of the immune response to cell surface antigens.
P. Lake (1976)
10.1016/0167-5699(86)90104-0
Strategies for cell-mediated immunotherapy of cancer: killing or help?
G. Forni (1986)
10.1038/268154A0
Long term culture of tumour-specific cytotoxic T cells
S. Gillis (1977)
Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.
C. Taswell (1981)
10.1084/JEM.159.5.1491
Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine
P. Frost (1984)
10.1016/B978-0-12-564504-1.50009-X
Limiting Dilution Assays for the Separation, Characterization, and Quantitation of Biologically Active Particles and Their Clonal Progeny
C. Taswell (1987)
10.1016/B978-0-12-341360-4.50058-5
AUGMENTATION OF HUMAN NATURAL KILLER CELLS WITH HUMAN LEUKOCYTE AND HUMAN RECOMBINANT LEUKOCYTE INTERFERON
J. Ortaldo (1982)
10.1002/IJC.2910240306
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti‐tumor immunity in vivo and of cytolytic T cells in vitro
K. Bosslet (1979)
Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.
D. Dialynas (1983)
Interleukin 2 is not sufficient as helper component for the activation of cytotoxic T lymphocytes but synergizes with a late helper effect that is provided by irradiated I-region-incompatible stimulator cells.
M. Reddehase (1982)
10.1016/0005-2787(74)90240-8
On the possibility of intercalation of aromatic amino acid residues into double-stranded DNA helix
John R. Jacobsen (1974)
Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
H. Fujiwara (1986)
10.1099/0022-1317-65-4-795
Newcastle disease virus: the effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants.
P. H. Russell (1984)
Enumeration of IL 2-secreting helper T cells by limiting dilution analysis, and demonstration of unexpectedly high levels of IL 2 production per responding cell.
R. Miller (1982)
Release of discrete interferons by cytotoxic T lymphocytes in response to immune and nonimmune stimuli.
M. Pasternack (1984)
10.1038/315315A0
Evidence for an increase in cosmogenic 10Be during a geomagnetic reversal
G. Raisbeck (1985)
Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response.
V. Schirrmacher (1981)
10.1016/S0065-230X(08)61034-9
Antigenic tumor cell variants obtained with mutagens.
T. Boon (1983)
10.1002/EJI.1830140913
The augmentation of tumor‐specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus‐reactive helper T cells
Y. Shimizu (1984)
10.1002/EJI.1830140419
Production of type I (α/β) interferon after virus infection of cloned, alloantigen‐sensitized mouse T lymphocytes
M. Cooley (1984)
10.1038/312548A0
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
S. Cobbold (1984)
Thymoma production of T cell growth factor (Interleukin 2).
J. Farrar (1980)
Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
M. Sensi (1984)
10.1002/1097-0142(197410)34:8+<1541::AID-CNCR2820340828>3.0.CO;2-G
Cell surface modification in the treatment of experimental cancer: Neuraminidase or concanavalin a
R. Simmons (1974)
10.1099/0022-1317-62-2-349
Interferon production in mouse spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus.
Y. Ito (1982)
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
P. von Hoegen (1989)
10.1038/329760A0
How T cells communicate
J. Breitmeyer (1987)
IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.
M. Sarmiento (1980)
10.1111/j.1365-3083.1983.tb00784.x
Effect of Interferon on Cell Proliferation and Generation of Cytotoxic Potential in Mixed Autologous and Allogeneic Lymphocyte Cultures
S. Argov (1983)
10.1016/0008-8749(87)90317-0
New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
P. von Hoegen (1987)
Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
M. Giovarelli (1985)
In vitro methods in cell mediated and tumor immunity
B. Bloom (1976)



This paper is referenced by
10.1002/1097-0142(19901001)66:7<1517::AID-CNCR2820660714>3.0.CO;2-I
Postoperative active specific immunization in colorectal cancer patients with virus‐modified autologous tumor‐cell vaccine. First clinical results with tumor‐cell vaccines modified with live but avirulent newcastle disease virus
W. Bohle (1990)
10.1016/0959-8049(95)96247-B
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
D. Ockert (1996)
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
V. Schirrmacher (1997)
10.3390/ijms18051103
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
V. Schirrmacher (2017)
10.1016/j.omto.2019.06.001
Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine
X. Xu (2019)
10.1089/CBR.1995.10.307
Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine.
T. A. Steele (1995)
10.1001/ARCHSURG.1990.01410150030006
Tumor immunization. Improved results after vaccine modified with recombinant interferon gamma.
R. Sigal (1990)
10.1007/978-3-642-80071-9_12
Immunotherapy of metastases.
V. Schirrmacher (1996)
10.2174/1876401000902010018
Ear Pinna : a privileged DNA electroporation site for inducing strong Th1 immune responses
J. Ni (2009)
10.3390/biomedicines4030016
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
V. Schirrmacher (2016)
10.1007/BF01741145
Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancer
P. Schlag (2005)
10.1002/IJC.2910590615
Effective anti‐metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with newcastle disease virus (NDV)
D. Plaksin (1994)
10.1016/0378-1135(94)90166-X
More than one component of the Newcastle disease virus particle is capable of interferon induction
K. Wertz (1994)
10.1023/A:1011856406683
Preliminary Results of Active Specific Immunization with Modified Tumor Cell Vaccine in Glioblastoma Multiforme
T. Schneider (2004)
Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns.
T. Ahlert (1990)
Immunobiology of Anticancer Virotherapy With Newcastle Disease Virus in Cancer Patients
Nemat Khansari (2017)
10.1111/j.1440-1681.2011.05662.x
Newcastle disease virus: A promising agent for tumour immunotherapy
Lixiang Zhao (2012)
10.3390/biomedicines8030061
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
V. Schirrmacher (2020)
10.1046/j.1440-1711.2000.00949.x
Computer‐assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences
C. Natale (2000)
10.3390/biomedicines7030066
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
V. Schirrmacher (2019)
10.1089/HYB.1993.12.559
Autologous tumor-cell vaccination and lymphokine-activated tumor-infiltrating lymphocytes (LAK-TIL).
P. Mallmann (1993)
10.1093/INTIMM/8.4.491
Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B.
V. Umansky (1996)
10.1007/978-3-642-74236-1_20
Active Specific Immunotherapy with Autologous Tumor Cell Vaccines Modified by Newcastle Disease Virus: Experimental and Clinical Studies
V. Schirrmacher (1989)
10.1002/IJC.2910460414
F11C antigen: A membrane marker able to distinguish two regressive and progressive variants from a rat colon adenocarcinoma
A. Caignard (1990)
10.1201/B14180-5
New Biological Therapeutics: Competitors or Collaborators of Viral Therapy for Human Cancers
J. G. Sinkovics (2004)
10.1155/2011/718710
Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy
Han Yuen Lam (2011)
Live viruses in cancer treatment.
J. Nemunaitis (2002)
10.1016/S0753-3322(00)80070-0
Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia.
S. Benefraim (2000)
10.1002/EJI.1830231032
Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses
C. Ertel (1993)
10.1007/S001310050384
METASTASIERTES NIERENZELLKARZINOM : UNGEWOHNLICHER VERLAUF NACH OPERATION UND AUTOLOGER TUMORZELLVAKZINIERUNG
W. Vogl (1999)
10.1517/14712598.5.8.1051
T cell-mediated immunotherapy of metastases: state of the art in 2005
V. Schirrmacher (2005)
10.1179/ISR.1989.14.3.291
Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing
V. Schirrmacher (1989)
See more
Semantic Scholar Logo Some data provided by SemanticScholar